DLC-1, a candidate tumor suppressor gene, inhibits the proliferation, migration and tumorigenicity of human nasopharyngeal carcinoma cells

International Journal of Oncology

Volumn 42, Issue 6, 2013, Pages 1973-1984

  Feng, Xiangling ^a   Li, Cui ^b   Liu, Weidong ^a   Chen, Huan ^a   Zhou, Wen ^a   Wang, Lei ^a   Zhu, Bin ^a   Yao, Kaitai ^a,c   Jiang, Xingjun ^b   Ren, Caiping ^a  

^a Central South University   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Biological function; Deleted in liver cancer 1 gene; Invasion; Microarray; Migration; Nasopharyngeal carcinoma

Indexed keywords

ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DLC 1 GENE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ACTINS; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GTPASE-ACTIVATING PROTEINS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; RECOMBINANT PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84876592010     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1885     Document Type: Article

References (42)

1. Chang ET and Adami HO: The enigmatic epidemiology of naso-pharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15: 1765-1777, 2006.
2. Yao KT: The application and prospect of nasopharyngeal carcinoma etiology. China Cancer 6: 3-4, 1997.
3. Lo KW, To KF and Huang DP: Focus on nasopharyngeal carcinoma. Cancer Cell 5: 423-428, 2004. (Pubitemid 38612865)
4. Wei WI and Sham JS: Nasopharyngeal carcinoma. Lancet 365: 2041-2054, 2005. (Pubitemid 40812341)
5. Tao Q and Chan AT: Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 9: 1-24, 2007. (Pubitemid 47398642)
6. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS and Popescu NC: Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 58: 2196-2199, 1998. (Pubitemid 28232908)
7. Durkin ME, Yuan BZ, Zhou X, et al: DLC-1: a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med 11: 1185-1207, 2007. (Pubitemid 350037059)
8. Lahoz A and Hall A: DLC-1: a signifcant GAP in the cancer genome. Genes Dev 22: 1724-1730, 2008. (Pubitemid 351915495)
9. Peng D, Ren CP, Yi HM, et al: Genetic and epigenetic alterations of DLC-1, a candidate tumor suppressor gene, in nasopharyngeal carcinoma. Acta Biochim Biophys Sin (Shanghai) 38: 349-355, 2006.
10. Seng TJ, Low JS, Li H, et al: The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene 26: 934-944, 2007.
11. Zhang H, Feng X, Liu W, et al: Underlying mechanisms for LTF inactivation and its functional analysis in nasopharyngeal carcinoma cell lines. J Cell Biochem 112: 1832-1843, 2011.
12. Zhou W, Feng X, Li H, et al: Functional evidence for a nasopha-ryngeal carcinoma-related gene BCAT1 located at 12p12. Oncol Res 16: 405-413, 2007.
13. Shao JY, Wang HY, Huang XM, et al: Genome-wide allelotype analysis of sporadic primary nasopharyngeal carcinoma from southern China. Int J Oncol 17: 1267-1275, 2000.
14. Song L and Wang H: Study on the tumor heterogeneity of naso-pharyngeal carcinoma cell line (SUNE-1). Chin J Cancer 17: 324-327, 1998.
15. Kim TY, Lee J W, Kim HP, et al: DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun 355: 72-77, 2007. (Pubitemid 46273368)
16. Wong CM, Yam JW, Ching YP, et al: Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res 65: 8861-8868, 2005. (Pubitemid 41377375)
17. Goodison S, Yuan J, Sloan D, et al: The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res 65: 6042-6053, 2005. (Pubitemid 40994388)
18. Yuan BZ, Jefferson AM, Millecchia L, Popescu NC and Reynolds SH: Morphological changes and nuclear transloca-tion of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells. Exp Cell Res 313: 3868-3880, 2007. (Pubitemid 47561896)
19. Ullmannova-Benson V, Guan M, Zhou X, et al: DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia 23: 383-390, 2009.
20. Loyo M, Brait M, Kim MS, et al: A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int J Cancer 128: 1393-1403, 2011.
21. Li G, Du X, Vass WC, Papageorge AG, Lowy DR and Qian X: Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). Proc Natl Acad Sci USA 108: 17129-17134, 2011.
22. Qian X, Li G, Asmussen HK, et al: Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specifc GTPase-activating protein activities. Proc Natl Acad Sci USA 104: 9012-9017, 2007. (Pubitemid 47175428)
23. Liao YC, Si L, deVere White RW and Lo SH: The phosphotyro-sine- independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol 176: 43-49, 2007. (Pubitemid 46041679)
24. Yam JW, Ko FC, Chan CY, Jin DY and Ng IO: Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res 66: 8367-8372, 2006. (Pubitemid 44449146)
25. Hall EH, Balsbaugh JL, Rose KL, Shabanowitz J, Hunt DF and Brautigan DL: Comprehensive analysis of phosphorylation sites in Tensin1 reveals regulation by p38MAPK. Mol Cell Proteomics 9: 2853-2863, 2010.
26. Deng YF, Zhou DN, Ye CS, Zeng L and Yin P: Aberrant expression levels of MTA1 and RECK in nasopharyngeal carcinoma: association with metastasis, recurrence, and prognosis. Ann Otol Rhinol Laryngol 121: 457-465, 2012.
27. Meng N, Li Y, Zhang H and Sun XF: RECK, a novel matrix metalloproteinase regulator. Histol Histopathol 23: 1003-1010, 2008.
28. Noda M, Oh J, Takahashi R, Kondo S, Kitayama H and Takahashi C: RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 22: 167-175, 2003. (Pubitemid 36561056)
29. Rohan PJ, Davis P, Moskaluk CA, et al: PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase. Science 259: 1763-1766, 1993. (Pubitemid 23114665)
30. Zhang Q, Muller M, Chen CH, Zeng L, Farooq A and Zhou MM: New insights into the catalytic activation of the MAPK phospha-tase PAC-1 induced by its substrate MAPK ERK2 binding. J Mol Biol 354: 777-788, 2005. (Pubitemid 41735501)
31. Lin SC, Chien CW, Lee JC, et al: Suppression of dual-speci-fcity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells. J Clin Invest 121: 1905-1916, 2011.
32. Ruan L, Li XH, Wan XX, et al: Analysis of EGFR signaling pathway in nasopharyngeal carcinoma cells by quantitative phosphoproteomics. Proteome Sci 9: 35, 2011.
33. Wan Y, Yang M, Kolattukudy S, Stark GR and Lu T: Activation of cAMP-responsive-element-binding protein by PI3 kinase and p38 MAPK is essential for elevated expression of transforming growth factor beta2 in cancer cells. J Interferon Cytokine Res 30: 677-681, 2010.
34. Tanioka Y, Yoshida T, Yagawa T, et al: Matrix metallopro-teinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superfcial oesophageal cancer. Br J Cancer 89: 2116-2121, 2003. (Pubitemid 38030912)
35. Koskensalo S, Louhimo J, Nordling S, Hagstrom J and Haglund C: MMP-7 as a prognostic marker in colorectal cancer. Tumour Biol 32: 259-264, 2011.
36. Koskensalo S, Mrena J, Wiksten JP, et al: MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol 31: 149-155, 2010.
37. Awakura Y, Nakamura E, Takahashi T, et al: Microarray-based identifcation of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. J Cancer Res Clin Oncol 134: 1363-1369, 2008.
38. Ikeda J, Oda T, Inoue M, et al: Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci 100: 429-433, 2009.
39. Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T and Sakai R: CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol 27: 7649-7660, 2007. (Pubitemid 350033670)
40. Chou J, Lin YC, Kim J, et al: Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis. Head Neck 30: 946-963, 2008. (Pubitemid 352008957)
41. Tulalamba W and Janvilisri T: Nasopharyngeal carcinoma signaling pathway: an update on molecular biomarkers. Int J Cell Biol 2012: 594681, 2012.
42. Dang CV: Links between metabolism and cancer. Genes Dev 26: 877-890, 2012.